Refine my results

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)

Rochlitz, C. ; Ruhstaller, T. ; Lerch, S. ; Spirig, C. ; Huober, J. ; Suter, T. ; Bühlmann, M. ; Fehr, M. ; Schönenberger, A. ; von Moos, R. ; Winterhalder, R. ; Rauch, D. ; Müller, A. ; Mannhart-Harms, M. ; Herrmann, R. ; Cliffe, B. ; Mayer, M. ; Zaman, K.

In: Annals of Oncology, 2011, vol. 22, no. 1, p. 80-85